去纤维钠（去纤苷）治疗什么病？

(Defibrinoside) is a single-chain sodium salt of polydeoxyribose ribonucleoside, which has anti-thrombotic, anti-ischemic, anti-inflammatory and pro-fibrinolytic properties. In clinical practice, the drug is mainly used for the treatment of hepatic veno-occlusive disease (HVOD).

It has been reported abroad that the application of defibrinated sodium in the treatment of severe HVOD is effective without significant toxicity. A foreign study first explored its application in the treatment of HVOD after HSCT. This study included 19 patients with sHVOD. The dosage of defibrotide is 5~60mg/kg per day, intravenous infusion, and the median usage time is 15d (2-61d). The results showed that 42% of patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%, and patients could tolerate defibrination well. Since then, multiple clinical trials have confirmed the effectiveness of defibrotide in the treatment of HVOD.

In 2000, a European research group (including 19 treatment centers) reported the efficacy of defibrotide sodium in 40 patients with HVOD, 28 of whom were patients with severe HVOD or multiple organ failure. The dosage of defibrinated sodium is 10~40 mg/kg/d, the median application time is 18 (2-71) days, and the median time of starting medication is +14 (-2+53) days after transplantation. The results showed that 22 cases (55%) achieved complete remission, and 17 cases (43%) survived +100 days.

In 2002, a multi-center collaborative group in the United States reported the results of 87 patients with severe HVOD and multiple organ failure after hematopoietic stem cell transplantation. The dosage was 5 to 60 mg/kg/d, and the median duration of medication was 15 days. As a result, 36% of patients achieved complete remission, and 35% of patients survived 100 days after transplantation. Both studies showed that defibrotide sodium has no obvious toxic side effects and is a safe and effective drug for the treatment of HVOD.

Recommended hot articles: /newsDetail/78639.html